# MX BIO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mx-bio

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.mx-bio.com/
- Total disclosed funding: $12M
- Latest round: Series B (Apr 21, 2026)
- Investors on record: 6

## About

Based in South Korea, MX BIO Inc. specializes in biotechnology solutions, focusing on developing and manufacturing diagnostic tools and therapeutic products for healthcare professionals and research institutions. MX BIO Inc. is a biotechnology company founded in 2018 and headquartered in Seoul, South Korea. The company is devoted to advancing diagnostic solutions and has successfully raised KRW 11.3 billion in Series B funding as of April 21, 2026. The CEO of the company is Jae Lee, who has a history of leadership in the biotech sector. MX BIO Inc. specializes in innovative biotechnology solutions, primarily focusing on the development and manufacturing of advanced diagnostic tools and therapeutic products. Their core offerings include proprietary assays and kits for the rapid and accurate detection of various biological markers essential in clinical diagnostics and research applications. Targeted at healthcare professionals, research institutions, and laboratories, these products enhance patient care and informed decision-making in medical settings, marketed across North America, Europe, and Asia to meet the rising demand for precise diagnostics in oncology, infectious diseases, and genetic testing.MX BIO Inc. generates revenue through a structured framework of direct-to-consumer and business-to-business transactions. The company primarily relies on the sale of its diagnostic products, often contracted with hospitals and laboratories under bulk purchase agreements or subscription models. The tiered pricing plans based on purchase volume allow healthcare providers access to their diagnostic kits at competitive rates, and revenue is further supported by partnerships with major distributors and healthcare organizations, facilitating a broader market reach.In March 2020, MX BIO Inc. raised KRW 2.8 billion in Series A funding. The company plans to utilize this funding to accelerate the construction of its GMP facilities and to acquire item certification. Additionally, MX BIO Inc. aims to launch new products designed to meet the ongoing demands of the healthcare market while targeting expansion into new geographic regions to increase its market presence.

## Funding rounds

- Series B, Apr 21, 2026, $7.6M — CKD Venture Capital, Shinhan Capital, HB Investment, Posco Investment, KB Securities
- Series A, Mar 2, 2020, $2.3M — CKD Venture Capital, Shinhan Capital, HB Investment, KB Securities
- Series A, Nov 1, 2019, $2.4M — CKD Venture Capital, Shinhan Capital, HB Investment, KB Securities
- Seed, Feb 1, 2019 — Posco Investment, Korea Tech Incubator for Startup

## Investors

- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Seed, Series B
- Korea Tech Incubator for Startup — Seed
- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series A, Series B
- Shinhan Capital (https://capitalatlas.ai/funds/shinhan-capital) — Series A, Series B
- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series A, Series B
- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series A, Series B